PATENT CLAIM ANALYSIS

Application Number: 15764687
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["514", "480000"]

Abstract:
Provided herein are methods that relate to a therapeutic strategy for treatment of cancer, and allergic, autoimmune, and inflammatory disorders including hematological malignancies. In particular, the methods include administration of a BTK inhibitor and with one or more inhibitor. For example, the one or more inhibitor may be a JAK inhibitor, a ASK1 inhibitor, a BRD4 inhibitor or an MMP9 inhibitor.

Claim (Index 4):
The method of  claim 1  wherein the disease is selected from the group consisting of a hematologic malignancy, leukemia, lymphoma chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin's lymphoma, indolent non-Hodgkin's lymphoma (iNHL), mantle cell lymphoma, follicular lymphoma (FL), lymphoplasmacytic lymphoma, and marginal zone lymphoma, rheumatoid arthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease (CORD), adult respiratory distress syndrome and asthma.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 90.0
- Lexical Diversity: 1.61364
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15319740', '14135812', '15105372', '14254010', '14570655']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.801824289053256
- 35 USC 102 Novelty (BERT): 0.5026693406269725
- Combined Prediction Score: 0.7719087942106276
- Mean Citation Score: 247.382998
- Max Citation Score: 260.51425
- Similarity Product: 186.5943259666115

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test